Gilead Sciences, Inc. or Merus N.V.: Who Manages SG&A Costs Better?

SG&A Cost Management: Gilead Sciences, Inc. vs. Merus N.V.

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Gilead Sciences, Inc. and Merus N.V. have demonstrated contrasting approaches to SG&A cost management.

Gilead Sciences, Inc.

Gilead Sciences has consistently maintained high SG&A expenses, peaking at approximately $6.1 billion in 2023. This represents a 104% increase from 2014, reflecting their expansive operational scale and investment in administrative capabilities.

Merus N.V.

Conversely, Merus N.V. has managed to keep its SG&A expenses significantly lower, with a peak of around $59.8 million in 2023. This is a staggering 1,454% increase from 2015, showcasing their rapid growth and strategic cost management.

Conclusion

While Gilead's expenses are higher, their scale justifies it. Merus, with its leaner approach, highlights efficient cost management in a growing company.